Company Monitoring Page for Novo-Nordisk

latest headlines for company on cafepharma

Novo Nordisk continues pushing beyond diabetes, netting PhII win for former Corvidia kidney program
Endpoints
Tue, 05/18/21 - 11:00 am
Tags:
Novo Nordisk, chronic kidney disease, clinical trials, ziltivekimab
Recall report: Novo Nordisk recalls samples of multiple insulin products after storage screw-up
Endpoints
Thu, 05/13/21 - 10:47 am
Tags:
insulin, Novo Nordisk, product recalls, FDA, Levemir, Tresiba, Fiasp, Novolog, Xultrophy
Novo Nordisk recalls sales rep samples sunk by Texas power outages
Fierce Pharma
Mon, 05/10/21 - 09:46 pm
Tags:
Novo Nordisk, Texas, drug reps
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Fierce Pharma
Wed, 05/5/21 - 11:09 am
Tags:
Novo Nordisk, Ozempic, drug launches, obesity
AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
Fierce Pharma
Wed, 05/5/21 - 10:50 am
Tags:
AbbVie, Humira, DTC advertising, television ads, Sanofi, Dupixent, Novo Nordisk, Rybelsus
Novo Nordisk ups forecasts after Q1 profit boost
Pharmaforum
Wed, 05/5/21 - 10:46 am
Tags:
Novo Nordisk, earnings
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Endpoints
Wed, 04/21/21 - 11:17 pm
Tags:
Novo Nordisk, diabetes, obesity, semaglutide, oral semaglutide, clinical trials
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Fierce Pharma
Mon, 04/12/21 - 10:58 pm
Tags:
reputation, pharma industry, Sanofi, Novo Nordisk, Roche, Eli Lilly, Bristol Myers Squibb
Big pharma freshens up
EP Vantage
Fri, 04/9/21 - 10:35 am
Tags:
Merck, Bristol Myers Squibb, Astellas, Novo Nordisk, AbbVie, Sanofi
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
Benzinga
Tue, 03/23/21 - 10:25 am
Tags:
Novo Nordisk, FDA, diabetes, semaglutide, RTF letters
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Fierce Biotech
Thu, 03/18/21 - 10:54 am
Tags:
Gilead Sciences, Novo Nordisk, NASH, R&D
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
Fierce Pharma
Sat, 03/13/21 - 10:19 pm
Tags:
COVID-19, pandemic, GSK, Novo Nordisk, Roche
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma
Sun, 03/7/21 - 01:27 pm
Tags:
Eli Lilly, tirzepatide, diabetes, Ozempic, Novo Nordisk, clinical trials
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Fierce Biotech
Thu, 03/4/21 - 10:05 am
Tags:
Eli Lilly, Novo Nordisk, tirzepatide, semaglutide, type 2 diabetes, clinical trials
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Fierce Pharma
Tue, 02/23/21 - 10:56 pm
Tags:
Eli Lilly, tirzepatide, Novo Nordisk, Ozempic, diabetes
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Thu, 02/11/21 - 10:43 am
Tags:
Novo Nordisk, semaglutide, obesity
Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds
Fierce Pharma
Thu, 02/4/21 - 10:43 am
Tags:
Novo Nordisk, drug manufacturing, APIs
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Yahoo/Global Newswire
Wed, 01/20/21 - 10:39 am
Tags:
Novo Nordisk, FDA, Ozempic, type 2 diabetes, semaglutide
Pharma TV ad spenders blow up December with spendiest month of 2020
Fierce Pharma
Wed, 01/6/21 - 10:50 am
Tags:
television ads, AbbVie, Humira, Novo Nordisk, DTC ads
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Pharmaforum
Wed, 01/6/21 - 10:42 am
Tags:
Novo Nordisk, Dicerna, gene silencing, liver disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.